

SUPPLEMENTAL MATERIAL TABLE OF CONTENTS

Supplemental Table 1. Availability of Biochemical Measures in Oral calcitriol and IV Vitamin D Analog Groups during Baseline Period and Follow-Up

Supplemental Table 2. Calcium, Phosphate, and Parathyroid Hormone Concentrations within Pre-Specified Ranges in Oral Calcitriol and IV Vitamin D Analog Groups over Time

Supplemental Table 3. As-Treated Comparison of Calcium, Phosphate, and Parathyroid Hormone Concentrations within Pre-Specified Ranges between Oral Calcitriol and IV Vitamin D Analog Groups during Follow-Up

Supplemental Table 4. Percent of Oral Calcitriol and IV Vitamin D Analog Patients Receiving Cinacalcet at Baseline, and Over the Ensuing 12 Months

Supplemental Table 5. Dose of IV Doxercalciferol During Follow-Up

Supplemental Table 6. Dose of Oral Calcitriol During Follow-Up

Supplemental Table 1. Availability of biochemical measures in oral calcitriol and IV vitamin D analog groups during baseline period and follow-up.

		Months before or after enrollment														
		-3	-2	-1	1	2	3	4	5	6	7	8	9	10	11	12
Calcium																
Oral	# of pts at beginning of interval	2280	2280	2280	2280	2245	2186	2143	2115	2071	2022	1988	1943	1900	1863	1818
	% of pts with data available	95%	88%	97%	93%	90%	90%	93%	92%	85%	94%	90%	93%	94%	83%	97%
IV	# of pts at beginning of interval	2280	2280	2280	2280	2251	2201	2162	2119	2073	2034	2002	1965	1906	1872	1825
	% of pts with data available	99%	96%	99%	98%	98%	97%	97%	98%	97%	96%	97%	96%	92%	95%	96%
Phosphate		-3	-2	-1	1	2	3	4	5	6	7	8	9	10	11	12
Oral	# of pts at beginning of interval	2280	2280	2280	2280	2245	2186	2143	2115	2071	2022	1988	1943	1900	1863	1818
	% of pts with data available	95%	88%	97%	93%	90%	90%	93%	93%	85%	94%	90%	93%	94%	83%	97%
IV	# of pts at beginning of interval	2280	2280	2280	2280	2251	2201	2162	2119	2073	2034	2002	1965	1906	1872	1825
	% of pts with data available	99%	96%	99%	98%	98%	97%	97%	97%	97%	96%	97%	96%	92%	96%	96%
iPTH		-3 to -1	1–3	4–6	7–9	10–12										
Oral	# of pts at beginning of interval	2280	2280	2143	2022	1900										
	% of pts with data available	99%	95%	95%	95%	95%										
IV	# of pts at beginning of interval	2280	2280	2162	2034	1906										
	% of pts with data available	100%	97%	96%	96%	95%										
iPTH: Intact parathyroid hormone																

Supplemental Table 2. Calcium, phosphate, and parathyroid hormone concentrations within pre-specified ranges in oral calcitriol and IV vitamin D analog groups over time. *N* and (%).

	Oral calcitriol				IV vitamin D			
	Months				Months			
	1–3	4–6	7–12	p-value*	1–3	4–6	7–12	p-value*
Calcium ≤10 mg/dl	1891 (95%)	1890 (95%)	1887 (95%)	0.93	1797 (90%)	1818 (91%)	1858 (93%)	<0.001
Phosphate 3–5.5 mg/dl	1287 (65%)	1273 (64%)	1289 (65%)	0.72	1235 (62%)	1231 (61%)	1231 (61%)	0.98
iPTH 150–600 pg/dl	1281 (69%)	1244 (67%)	1285 (69%)	0.13	1406 (72%)	1388 (72%)	1423 (73%)	0.31
All three within range^	821 (44%)	804 (43%)	831 (45%)	0.51	806 (42%)	830 (43%)	866 (45%)	0.04
<p>Includes only patients with at least one laboratory value for each laboratory parameter during all three time intervals; p-values reflect comparisons between time periods within each group.</p> <p>iPTH: Intact parathyroid hormone</p> <p>*Cochran’s test. ^Calcium, phosphate, and iPTH all within specified range.</p>								

Supplemental Table 3. As-treated comparison of calcium, phosphate, and parathyroid hormone concentrations within pre-specified ranges between oral calcitriol and IV vitamin D analog groups during follow-up. *N* and (%).

	Months 1–3			Months 4–6			Months 7–12		
	Oral calcitriol	IV vitamin D	p-value *	Oral calcitriol	IV vitamin D	p-value *	Oral calcitriol	IV vitamin D	p-value *
Calcium ≤10 mg/dl	1144 (95%)	882 (90%)	<0.001	1057 (95%)	813 (92%)	<0.001	969 (94%)	746 (93%)	0.23
Phosphate 3-5.5 mg/dl	794 (66%)	625 (64%)	0.21	741 (67%)	571 (64%)	0.23	701 (68%)	503 (62%)	0.01
iPTH 150-600 pg/dl	875 (76%)	725 (76%)	0.66	803 (76%)	636 (74%)	0.41	769 (76%)	623 (79%)	0.16
All three within range[^]	568 (50%)	428 (45%)	0.02	542 (51%)	387 (45%)	0.009	507 (50%)	377 (48%)	0.29
<p>Patients receiving cinacalcet on or after their index date, those in the IV vitamin D analog group who switched to oral calcitriol in the follow-up period, and those in the oral calcitriol group who switched back to an IV vitamin D analog, were excluded (oral calcitriol, n=1271; IV vitamin D, n=1001).</p> <p>iPTH: Intact parathyroid hormone.</p> <p>p-values reflect differences between oral calcitriol and intravenous vitamin D analog groups within each time period.</p> <p>* Chi-Square text. ^ Calcium, phosphate, and iPTH all within specified range.</p>									

Supplemental Table 4. Percent of oral calcitriol and IV vitamin D analog patients receiving cinacalcet at baseline, and over the ensuing 12 months.

	Index date	1–3 months	4–6 months	7–12 months
Oral calcitriol	23%	30%	34%	39%
Intravenous vitamin D	23%	28%	30%	36%
p-value		0.11	0.004	0.04
p-values reflect comparisons between oral calcitriol and IV vitamin D analog groups within each time period. *Chi-Square test.				

Supplemental Table 5. Dose of IV doxercalciferol during follow-up.

	Doxercalciferol users (N)	Mean dose (mcg) per treatment	Median dose (mcg) per treatment
Months 1–3	2106	3.39 ± 2.28	2.74 [1.95, 4.49]
Months 4–6	1910	3.54 ± 2.55	2.95 [1.93, 4.61]
Months 7–12	1186	3.58 ± 2.65	2.95 [1.74, 4.82]
Data represented as means ± standard deviation (SD) or median [25th, 75th percentile].			

Supplemental Table 6. Dose of oral calcitriol during follow-up.

	Oral calcitriol users (N)	Mean dose (mcg) per treatment	Median dose (mcg) per treatment
Months 1–3	2167	0.61 ± 0.29	0.52 [0.47, 0.76]
Months 4–6	1975	0.69 ± 0.39	0.64 [0.46, 0.97]
Months 7–12	1814	0.78 ± 0.50	0.70 [0.42, 1.03]
Data represented as means ± standard deviation (SD) or median [25th, 75th percentile].			